Sponsor of the Day:
Jerkmate
https://medcitynews.com/2026/04/travere-therapeutics-filspari-sparsentan-fda-approval-rare-kidney-disease-proteinuria-fsgs-tvtx/
Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease - MedCity...
Apr 16, 2026 - Travere Therapeutics’ Filspari is now the first FDA-approved drug for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. Analysts project the...
rare kidney diseasebouncing backtrial failurewins firstfda approval
https://www.biopharmadive.com/news/travere-fda-approve-flispari-fsgs-kidney-disease/817415/
Travere wins long-awaited approval for kidney disease drug | BioPharma Dive
The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity believed to be worth more than $1...
drug biopharma divewins longkidney diseasetravereawaited
https://www.statnews.com/2026/04/16/biotech-news-cochrane-review-reignites-alzheimers-amyloid-war/
Medicare, Travere, Cochrane, Roche, Eli Lilly: Readout Newsletter
Apr 16, 2026 - Today's biotech news covers another Elevidys trial, FDA reconsidering peptides, and more debate over Alzheimer's amyloid plaques
eli lillyreadout newslettermedicaretraverecochrane
https://travere.com/rare-life/kevin/
Kevin | Travere
Mar 30, 2026 - A tale of racial bias that delayed a diagnosis
kevintravere
https://www.genengnews.com/companies/travere-therapeutics/
Travere Therapeutics Archives - GEN - Genetic Engineering and Biotechnology News
therapeutics archives gengenetic engineeringbiotechnology newstravere
https://travere.com/our-company/who-we-are/
Who We Are | Travere
Apr 15, 2026 - Travere Therapeutics (TVTX) is a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare...
travere
https://www.statnews.com/2026/04/16/travere-therapeutics-kidney-disease-fda-approval/
Travere drug doesn’t improve kidney function. The FDA still approved it | STAT
The agency has taken heat for not showing enough regulatory flexibility. In the case of Filspari, it showed too much.
kidney functiontraveredrugimprovefda
https://travere.com/
Travere Therapeutics | In Rare For Life
Apr 14, 2026 - Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare...
traveretherapeuticsrarelife